Peyote has been used as medicine for centuries by Indigenous peoples in the Americas, primarily to treat addiction, spiritual distress, and the psychological wounds of historical trauma. Modern research is now catching up, investigating whether mescaline, the primary psychoactive compound in peyote, could treat depression, anxiety, PTSD, and substance use disorders. No mescaline-based therapy has been approved by any regulatory agency, but early evidence from surveys and clinical studies suggests real therapeutic potential.
How Mescaline Works in the Brain
Mescaline produces its effects by activating serotonin receptors in the brain, specifically a type called 5-HT2A. When mescaline binds to these receptors on brain cells in the cortex, it triggers profound shifts in consciousness, emotion, and cognition. All classic psychedelics (including psilocybin and LSD) work through this same receptor, but mescaline activates a specific signaling pathway inside the cell that non-psychedelic compounds targeting the same receptor do not. This unique activation pattern is what produces the altered states of awareness that appear to be linked to therapeutic benefit.
After oral ingestion, mescaline reaches peak blood concentration in about two hours, with noticeable effects beginning around one hour. The compound has a half-life of roughly 3.5 hours, but its subjective effects last far longer than that timeline might suggest, averaging about 11 hours at a full dose. That’s significantly longer than psilocybin (about 5 hours) or LSD (about 8 hours), largely because mescaline takes longer to reach its peak and sustains a broader plateau of effects before tapering off.
Traditional Indigenous Uses
For the Native American Church and other Indigenous communities, peyote is not simply a drug but a sacrament with deep medicinal significance. It has been used in structured ceremonial settings to treat alcoholism, spiritual illness, and the cumulative psychological toll of colonization and displacement. These ceremonies are communal, guided by trained leaders, and integrated into a broader framework of prayer, song, and social support. Peyote remains a source of cultural confidence and identity for many tribal communities, and its religious use is legally protected in the United States under the American Indian Religious Freedom Act.
Research published in the American Journal of Psychiatry examined peyote ceremonies as a treatment for alcoholism among American Indians and found that the ceremonial context offered specific advantages for addressing the unique challenges faced by Indigenous people struggling with alcohol. The authors stopped short of calling peyote a cure but recognized it as a meaningful therapeutic tool within its cultural framework.
Depression, Anxiety, and PTSD
The most detailed modern evidence comes from a large survey study of people who used mescaline in naturalistic (non-clinical) settings. Among respondents who reported having a psychiatric condition at the time of their mescaline experience, 86% of those with depression said their symptoms improved afterward. For anxiety, that figure was 80%. Among people with PTSD, 76% reported improvement.
The study also examined what happened during the experience that predicted improvement. For depression and anxiety, the strongest predictor was the intensity of psychological insight: moments of deep personal understanding or realization during the experience. People who reported more intense insight were roughly 2.5 times more likely to report lasting improvement in depression. For PTSD, the pattern was different. Mystical-type experiences, characterized by feelings of unity, transcendence, and deep meaning, were the strongest predictor of symptom relief, with those reporting intense mystical experiences nearly four times more likely to improve.
These are self-reported outcomes, not data from controlled clinical trials, so they carry important limitations. People who seek out mescaline may already be motivated to change, and memory of improvement can be biased. Still, the effect sizes were moderate to large, which is notable even in survey research.
Alcohol and Substance Use Disorders
Treating addiction is one of peyote’s oldest documented medical applications and one of its most promising modern ones. In the same naturalistic survey, 76% of respondents with alcohol misuse or alcohol use disorder reported improvement after their mescaline experience. For other drug misuse, 68% reported improvement. The intensity of psychological insight during the experience was again the key factor: people with stronger insight experiences were over three times more likely to report improvement in both alcohol and drug problems.
This aligns with the longstanding use of peyote ceremonies for alcoholism recovery in Indigenous communities, where the combination of the psychedelic experience, communal support, and spiritual meaning appears to create conditions that support lasting behavioral change.
How Mescaline Compares to Other Psychedelics
A randomized, double-blind clinical study directly compared mescaline to psilocybin and LSD in healthy volunteers. At equivalent doses, all three substances produced nearly identical peak effects, with participants rating the intensity at 83% to 87% of maximum on standardized scales. The key difference was duration. Mescaline’s effects lasted an average of 11.1 hours, compared to 8.2 hours for LSD and 4.9 hours for psilocybin.
Whether a longer experience is therapeutically better or worse remains an open question. A longer session means more time for the kind of deep psychological processing that seems linked to improvement in depression and addiction. It also means a greater commitment of time and clinical resources, which could make mescaline-assisted therapy more logistically challenging than psilocybin-assisted therapy. For patients, the practical difference is spending most of a full day in an altered state rather than half a day.
Physical Effects and Safety Concerns
Psychedelics as a class are considered physiologically safe with low toxicity and low addiction potential. Mescaline temporarily raises blood pressure and heart rate in a dose-dependent way, similar to psilocybin and LSD. In healthy people under controlled conditions, these cardiovascular changes are short-term and clinically insignificant.
There are, however, theoretical concerns that deserve attention. Mescaline activates serotonin receptors found not only in the brain but also in the heart and blood vessels. Activation of one receptor subtype (5-HT2B) has been linked to heart valve problems with repeated, long-term exposure to other drugs that target it. Psychedelics also stimulate the sympathetic nervous system, producing effects similar to adrenaline. At very high doses in uncontrolled settings, severe blood vessel constriction has been reported.
Existing clinical trials have excluded people with cardiovascular disease, which means the safety data simply does not apply to anyone with heart conditions, blood clotting disorders, or related problems. For healthy individuals using mescaline in controlled doses, the physical risks appear minimal based on current evidence. The psychological risks, including intense anxiety, confusion, or distressing experiences during the session, are managed in clinical and ceremonial settings through preparation, guidance, and a supportive environment.
Legal Status and Access
Mescaline is classified as a Schedule I controlled substance in the United States, meaning it is illegal to manufacture, possess, or distribute outside of the specific religious exemption granted to members of the Native American Church. Peyote itself is also a protected plant with limited wild populations, concentrated primarily in southern Texas and northern Mexico, making conservation an additional concern. No clinical trials have yet been completed that would support regulatory approval of mescaline as a prescription therapy, though the growing body of evidence is building the case for formal investigation.